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Abstract
Background: The distribution of airway responsiveness in a general population of non-smokers
without respiratory symptoms has not been established, limiting its use in clinical and
epidemiological practice. We derived reference equations depending on individual characteristics
(i.e., sex, age, baseline lung function) for relevant percentiles of the methacholine two-point dose-
response slope.
Methods: In a reference sample of 1567 adults of the SAPALDIA cross-sectional survey (1991),
defined by excluding subjects with respiratory conditions, responsiveness during methacholine
challenge was quantified by calculating the two-point dose-response slope (O'Connor). Weighted
L1-regression was used to estimate reference equations for the 95th , 90th , 75th and 50th percentiles
of the two-point slope.
Results: Reference equations for the 95th , 90th , 75th and 50th percentiles of the two-point slope
were estimated using a model of the form a + b* Age + c* FEV1 + d* (FEV1)2 , where FEV1
corresponds to the pre-test (or baseline) level of FEV1. For the central half of the FEV1 distribution,
we used a quadratic model to describe the dependence of methacholine slope on baseline FEV1.
For the first and last quartiles of FEV1, a linear relation with FEV1 was assumed (i.e., d was set to
0). Sex was not a predictor term in this model. A negative linear association with slope was found
for age. We provide an Excel file allowing calculation of the percentile of methacholine slope of a
subject after introducing age – pre-test FEV1 – and results of methacholine challenge of the subject.
Conclusion: The present study provides equations for four relevant percentiles of methacholine
two-point slope depending on age and baseline FEV1 as basic predictors in an adult reference
population of non-obstructive and non-atopic persons. These equations may help clinicians and
epidemiologists to better characterize individual or population airway responsiveness.
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Background
Description of normal airway responsiveness in a general
population is a recent concept [1]. However its use in
clinic or in epidemiological studies is limited by the lack
of established norms (as percentiles) of the distribution of
airway reactivity [2] according to the age, sex and airway
caliber of the subjects [3].
The conventional method to measure bronchial respon-
siveness is to perform a bronchochallenge test where FEV1
is measured at increasing levels of methacholine [4] up to
a maximal dose of 2 mg and to evaluate the resulting
dose-response curve. Results of the test are usually
expressed by an index of responsiveness, the provocating
dose (PD20) or concentration (PC20) producing a 20%
fall of FEV1. A subject is defined to be hyperreactive if, at
any of the methacholine levels tested, his/her FEV1 falls
below 80% of the baseline value. In epidemiological stud-
ies, however, the concept of hyperreactivity has substan-
tial limitations since the majority of subjects do not reach
the critical threshold level so that their degree of respon-
siveness cannot be defined in terms of a critical dose [5].
In order to obtain a simple index of non-specific airway
reactivity for every subject (hyperreactive or normal),
O'Connor et al [6] defined the slope of the dose-response
curve as the ratio between percent decline of FEV1 (from
the post-saline value to the value measured after the final
methacholine dose administered) and the final cumula-
tive dose of methacholine. For both asthmatic and normal
people this simple dose-response slope provides a good
summary of each subject's dose-response curve [7].
The distribution of hyperreactivity or of airway respon-
siveness in a general population sample has been
described in several studies [6,8,9]. For tests performed
with methacholine or with histamine, non-specific airway
responsiveness shows a unimodal skewed distribution.
Although asthmatic subjects tend to lie in the "reactive"
tail of the distribution, there is a considerable overlap
between the distributions of asthmatic and non-asthmatic
subjects. Some authors suggest that this unimodal distri-
bution reflects several overlapping clinical states between
normal subjects and symptomatic asthmatics [10]. How-
ever, apart from clinical state many individual predictive
factors influence the degree of bronchial responsiveness.
Whereas age has been investigated in many studies
[2,5,11-16], the exact influence of aging on reactivity is
still not clear. Its estimated effect appears to depend on
whether other possible confounding variables such as
baseline lung function or smoking status are simultane-
ously taken into account. Sex appears to be another
important predictive factor: women seem to be more reac-
tive than men [5,12,14-16], but adjusting for possible
confounding factors may explain some of this difference.
Pre-test FEV1 is considered as a major parameter influenc-
ing bronchial responsiveness [11,12,14-16]. However
many other potential variables appear to play a role, such
as smoking status [11,13-15,17], geographic characteris-
tics [2,11], atopic status [14-16], occupational exposure to
inhalation irritants [18], presence of chronic respiratory
conditions or prior asthma [19], or recent upper airway
infection [19]. These findings indicate that bronchial
responsiveness, as described by PD20, PC20 or dose-
response slope, may be influenced by a wide range of fac-
tors that in turn, may substantially affect its interpreta-
tion.
Data from the asymptomatic never smoking participants
of the SAPALDIA cross-sectional study (1991) have
already been used by Brändli [20,21] to derive reference
equations for mean values and lower limits of normal of
spirometric lung function. In this paper we use data of the
methacholine challenge test from a selected sample of
"normal" participants of the SAPALDIA sample to estab-
lish reference equations for some important percentiles of
methacholine slope depending on important individual
characteristics (i.e., sex, age and baseline lung function).
Methods
SAPALDIA (Swiss Study on Air Pollution and Lung Dis-
eases in Adults) is a multicenter study designed to investi-
gate the relationship between exposure to air pollutants
and respiratory symptoms or diseases. The eight study
areas participating in the project were chosen to represent
the variety of environmental conditions found in Switzer-
land concerning geography, climate, degree of urbanisa-
tion and air pollution. The study was approved by the
institutional review board for human investigations of the
different areas. In the cross-sectional part performed in
1991, a random sample of adults 18 to 60 years old were
invited to take part in the study. 9651 subjects were
included in the study, representing 59% of all eligible sub-
jects. Health assessment included a detailed question-
naire, computer-based spirometric tests, methacholine
bronchial challenge and skin allergy tests to 8 inhalative
allergens. Details on the methodology of these assess-
ments are given elsewhere [22].
Spirometry measurements were done using a Sensor-Med-
ics 2200 pulmonary function system SP (Bilthoven, The
Netherlands). This is an open sensor device which meets
the quality criteria of the American Thoracic Society. The
Sensor-Medics spirometer displays an error code after
each forced expiration to inform the technician about the
acceptability of the maneuver and the reproducibility
between the trials using the standard quality criteria
defined by the American Thoracic Society [23]. The trials
were recorded electronically on a personal computer as
they were done. Calibration was done at least once daily,Respiratory Research 2005, 6:131 http://respiratory-research.com/content/6/1/131
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using a 3-liter syringe. All the spirometry technicians were
trained together according to a standardized protocol and
were tested on volunteers [24]. Each of the following cri-
teria was sufficient for excluding a subject from the meth-
acholine test: a) a baseline FEV1 / FVC ratio of less than
80% of the ECCS-norm [25], b) a baseline FEV1 of less
than 70% of the ECCS-norm, c) pregnancy or breast feed-
ing, d) a myocardial infarction within the three months
preceding the SAPALDIA examination, e) severe heart fail-
ure under treatment, f) treatment with β-blockers includ-
ing eye-drops, g) refusal to participate. These exclusions
and the requirement of having complete and valid data on
lung function and bronchial responsiveness reduced the
sample size to 6942. Non-specific bronchial reactivity was
tested using methacholine chloride (Provocholine®  ,
Roche, Nutley, New Jersey, USA) prepared in 0.39, 1.56,
6.25, and 25.0 mg/ml solutions in a phosphate buffer
without phenol. Increasing concentrations of metha-
choline were administered through an aerosol dosimeter
(Mefar MB3, Bovezzo, Italy) up to a cumulative dose of 2
mg (8.37 µmol). With each inhalation, approximately
0.01 ml was delivered to the subject. The first dose inhaled
by the subject was a saline control. The schedule was then
4 inhalations of methacholine of 0.39 mg/ml (total dose
0.016 mg), 3 inhalations of 1.56 mg/ml (cumulative dose
0.062 mg), 3 inhalations of 6.25 mg/ml (cumulative dose
0.25 mg), 3 inhalations of 25 mg/ml (cumulative dose 1
mg), and 4 inhalations of 25.0 mg/ml (total cumulative
dose 2 mg). If a decrease in FEV1 of more than 10% from
the baseline level occurred at any intermediate point of
the test, smaller increments (i.e., halving the doses and
doubling the number of inhalations) were introduced.
Testing continued until the final dose of 2 mg was admin-
istered or until FEV1 had fallen by 20% or more. Under
this protocol the cumulative doses of methacholine con-
verted in micromoles at each level were 0, 0.065, 0.26,
1.05, 4.18, and 8.37. At each level, the subjects were asked
to inhale slowly from their functional residual capacity up
to their vital capacity. The subjects were instructed to keep
a full inspiration for 4 seconds before a slow normal exha-
lation. After each dose level of methacholine, 2 forced
expiratory maneuvers were performed at 1 and 2 minutes
after the end of the methacholine inhalation and the best
of the two FEV1 values was considered [26].
Methacholine responsiveness was quantified by calculat-
ing the two-point dose-response slope as defined by
O'Connor [6]. Slope is defined as the percentage of
decline of FEV1 from the post-saline value to the value
measured after the final methacholine dose administered
divided by the final cumulative methacholine dose
administered. Figure 1 provides a schematic diagram illus-
trating the relationship between the two-point dose
response slope (expressed in % decline of FEV1 divided by
the final cumulative methacholine dose administered)
and PD20 (provocating dose in mg producing a 20% fall
of FEV1). The figure demonstrates that higher reactivity is
indicated by a higher value of slope. The horizontal line
drawn at a slope of 2.39% decrease/µmol represents the
threshold commonly used to define bronchial hyperreac-
tivity (20% decrease of FEV1 after a cumulative metha-
choline dose of ≤ 2 mg).
Of the participants who performed the methacholine test,
only 1567 were included in the reference sample after
applying the following exclusion criteria: a) current or
former smoking: (i.e., having smoked 20 or more packs of
cigarettes or more than 360 g of tobacco); b) a prior diag-
nosis of asthma or report of symptoms related to asthma or
bronchitis  (i.e., wheezing in the last 12 months and/or
shortness of breath at rest in the last 12 months and/or
nocturnal attacks of shortness of breath in the last 12
months and/or attacks of asthma in the last 12 months
and/or current asthma medication and/or cough or
phlegm on most days of at least three months of the year);
c) atopy: defined by the presence of at least one positive
reaction to the eight inhalant allergens tested in a skin
prick test (subjects with missing results in this test were
also excluded); d) recent respiratory infection (i.e., anamne-
sis of a respiratory infection within three weeks prior to
the methacholine test).
Graphic representation of the relationship between the two- point dose response slope and PD20 Figure 1
Graphic representation of the relationship between 
the two-point dose response slope and PD20. This fig-
ure shows the relationship between the two-point dose 
response slope and PD20. The horizontal line drawn at a 
slope of 2.39% decrease/µmol represents the "cut-off" 
threshold commonly used to define bronchial hyperreactivity 
(20% decrease of FEV1 after a cumulative methacholine dose 
of ≤ 2 mg).
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Weighted L1-regression was used to estimate percentile
functions. This method consists of finding the model
parameters which minimize a given weighted sum of
absolute residual values. For instance, estimating the
model for the 75th percentile is achieved by assigning the
absolute values of positive residuals three times the
weight of the absolute values of negative residuals. In gen-
eral, if the m-th percentile is to be estimated, absolute val-
ues of positive residuals are given a weight proportional to
1/(100-m) and absolute values of negative residuals a
weight proportional to 1/m. Details of this method are
described elsewhere [27-29]. To test whether a given
model could be improved by adding an additional predic-
tor term, we defined a dichotomous variable U taking the
value 1 for observations with methacholine slopes exceed-
ing the respective percentile estimates and the value 0 for
all other observations. A logistic regression model incor-
porating the covariate part of the underlying percentile
model along with the additional predictor term was then
computed. If the additional predictor term was significant
then it was added to the percentile model. These methods
have already been applied in a similar context to estimate
percentile equations for lung function [21].
We tested the performance of this approach in identifying
asthmatics using the 90th percentile of slope as threshold
in subjects who answered positively to the double ques-
tion: "Have you ever had asthma? Was this confirmed by
a doctor?" and performed methacholine test (i.e. fulfilled
initial inclusion criteria mentioned above). For both men
and women of this subsample, the percentage of subjects
whose slopes exceeded this threshold was compared to
the percentage of subjects usually defined as hyperreactive
(i.e., with a positive response to the methacholine test
based on a fall of 20% of FEV1 during the test).
Results
The different stages leading to the selection of the refer-
ence sample are described in Table 1. Only 1567 persons,
representing 20.9% of all participants of the metha-
choline bronchial challenge fulfilled all criteria. The
major part of subjects excluded were current or former
smokers.
Characteristics of the study population are provided in
Table 2. It included a higher proportion of women
(60.9%) than in the whole methacholine test sample
Table 2: Distribution of basic predictor variables in the reference sample, SAPALDIA cross-sectional study, 1991
Men (n = 612) Women (n = 955) Entire reference sample (n = 1567)
<30 yrs 31.7% 20.8% 25.1%
30–40 yrs 24.8% 20.5% 22.2%
40–50 yrs 25.5% 27.9% 26.9%
≥50 yrs 18.0% 30.8% 25.8%
Height, mean (SD) 176.1 (6.7) 163.5 (6.5) 168.4 (9.0)
Weight, mean (SD) 75.2 (10.2) 61.6 (10.6) 66.9 (12.4)
FEV1, mean (SD) 4.33 (0.67) 3.10 (0.54) 3.58 (0.84)
PD20 prevalence* 4.4% 14.6% 10.6%
* PD20 prevalence denotes prevalence of subjects with a fall of 20% or more in FEV1 during the methacholine test
Table 1: Definition of the study sample, SAPALDIA cross-sectional study, 1991
Men Women Total
Whole SAPALDIA sample 4743 (100%) 4908 (100%) 9651 (100%)
- subjects with incomplete data on lung function and bronchial 
responsiveness*
3446 (72.7%) 3496 (71.2%) 6942 (71.9%)
- current or former smokers 1278 (26.9%) 1770 (36.1%) 3048 (31.6%)
- subjects with a prior diagnosis of asthma or symptoms related to asthma 
or bronchitis
1052 (22.2%) 1428 (29.1%) 2480 (25.7%)
- subjects with a positive or missing skin test 733 (15.5%) 1107 (22.6%) 1840 (19.1%)
- subjects with recent respiratory infection 612 (12.9%) 955 (19.5%) 1567 (16.2%)
Total of the study sample 612 (12.9%) 955 (19.5%) 1567 (16.2%)
* exclusion criteria from methacholine testing were FEV1/FVC ratio less than 80% of the ECCS-norm, FEV1 of less than 70% of the ECCS-norm, 
incomplete data on lung function, pregnancy or breast feeding, a myocardial infarction within the 3 months preceding the examination, being treated 
for severe heart failure, being treated with β-blockers including eye-drops, or refusal to participate; subjects with incomplete data on methacholine 
test were also excluded.Respiratory Research 2005, 6:131 http://respiratory-research.com/content/6/1/131
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(49.4%), explained by their lower prevalence of current or
former smoking. A scatter plot of methacholine slope vs.
baseline FEV1 (all subjects) is given in Figure 2.
Prediction equations of 95th , 90th , 75th and 50th percen-
tiles of the two-point slope are given in Table 3. The cor-
responding curves for 40 years old subjects are
represented in Figure 3. Prediction equations were derived
involving age and pre-test (or baseline) FEV1. Between the
lower and upper quartile of FEV1, these models are of the
form: a + b* Age + c* FEV1 + d* FEV1
2 , whereas no quad-
ratic term in FEV1 is used below the 1st and above the 3rd
quartile. We thus used natural quadratic splines with
knots at the lower and upper quartiles of FEV1 to describe
the dependency of percentiles of methacholine slope on
baseline FEV1. Therefore, up to the first quartile of FEV1,
each percentile curve of slope for a given age is described
by a straight line. Another straight line describes the per-
centile curve for FEV1-values above the upper quartile.
These two straight line segments are connected by a parab-
ola segment in such a way that the transition between the
different pieces is smooth. Although the coefficients a and
c have to vary between the three intervals, the smoothness
requirement imposes linear restrictions on them. On the
other hand, the coefficient b has the same value every-
where, since the association between slope and age
appeared to be approximately linear for all percentiles
considered. Consequently, the curves for figure 3 would
have to be shifted downward and upward for ages higher
and lower than 40 years, respectively. The model shows
that, with lower pre-test values of FEV1, level and spread
of the percentiles increases. A horizontal line drawn at y=
2.39% decrease/µmol represents the threshold commonly
used to define bronchial hyperreactivity (20% decrease of
FEV1 after a cumulative methacholine dose of ≤ 8.37
µmol). A higher proportion of subjects belong to this
"hyperreactive" category at lower values of FEV1 or lower
values of age. Consequently a higher proportion of
women are defined as "hyperreactive" (Table 3). We pro-
vide an additional Excel file allowing calculation of the
percentile of methacholine slope of a subject after intro-
ducing his/her age, pre-test FEV1, and results of metha-
choline challenge (i.e. methacholine total cumulative
dose and percentage of FEV1 decline at this total cumula-
tive dose) (Additional file 1).
Among subjects with physician-diagnosed asthma (n =
411), the percentage of subjects with a fall of 20% or more
during the methacholine test was significantly higher in
women than in men (58.8% vs. 43.8%, p < 0.01). In the
same population, percentages of subjects above the 90th
percentile of methacholine slope from the model includ-
ing FEV1 did not differ between both sexes (51.0% vs.
51.2%, p = 0.98).
Discussion
Previous studies have demonstrated that non-specific
bronchial responsiveness to methacholine may be influ-
enced by a number of factors [2,5,11-19]. On the basis of
Percentiles of methacholine slope as a function of pretest  level of FEV1 (among persons of reference sample aged 40  years) Figure 3
Percentiles of methacholine slope as a function of 
pretest level of FEV1 (among persons of reference 
sample aged 40 years). This figure shows the percentiles 
of methacholine slope as a function of pretest level of FEV1 
(among persons of reference sample aged 40 years). The 
horizontal line defines the threshold between "hyperreac-
tive" and "normal" subjects as defined by a 20% fall of FEV1 
from the baseline value before or at the maximal metha-
choline dose. The scale of pretest level of FEV1 extends from 
below the 1 st percentile to above the 99 th percentile of 
pretest level of FEV1 in our reference sample.
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a review of the literature we excluded subjects presenting
characteristics that may influence bronchial reactivity in a
"non-physiological" way from our study population:
smokers and former smokers, anamnestic asthmatic or
bronchitic subjects, atopics, and persons who reported a
recent respiratory infection. Moreover, the methacholine
challenge was not performed in subjects with spirometric
evidence of airway obstruction. Our preliminary analysis
showed that among the potential predictor variables con-
sidered (i.e., sex, age, height, weight, FEV1, FVC, FEV1 /
FVC, FEF25–75%, FEF25–75% / FVC), sex, age and either FEV1,
FEF25–75%, or FEF25–75% / FVC had the strongest explana-
tory power (results not shown). Using pre-test FEV1 in
addition to basic variables (sex, age, and height) improves
prediction equations for methacholine reactivity, proba-
bly due to multiple factors. In subjects with restrictive syn-
drome, whatever the etiology, airway calibre is better
described by absolute values of FEV1 than by the height or
weight of subjects. Moreover, the underlying mechanisms
of bronchial responsiveness to a pharmacological agent
are complex and multifactorial. Several studies suggested
that, apart from lung size, other important determinants
of non specific bronchial hyperresponsiveness are airway
geometry and properties of smooth muscles. Wassmer
[15] showed in an adult German population that BHR
(defined by a fall in 10% or 20% of FEV1 in methacholine
challenge) or bronchial responsiveness (described by
dose-response slope) is most strongly predicted by lung
function parameters. In a study analyzing hyperreactivity
in a large random adult population, Britton [16] showed
that FEV1, FEV1 %predicted and FEV1 / FVC were strongly
and independently related to BHR, identifying with vary-
ing degrees of overlap separate groups of individuals at
increased risk of hyperreactivity. In our analysis, however,
FEV1 / FVC was not significantly associated with metha-
choline slope. This may be explained by the exclusion of
obstructive and atopic subjects.
An independent significant effect of age on bronchial
methacholine dose-response slope is seen in our popula-
tion study even after correction for FEV1, showing a nega-
tive cross-sectional association between slope and age
after adjustment for differences in FEV1. This is an interest-
ing result per se, given that an independent effect of age
Table 4: Estimated equations of the 95th , 90th , 75th and 50th percentiles of methacholine slope given age and pretest level of FEV1 
(litres), SAPALDIA cross-sectional study, 1991
Slope95 = 34.70 - 0.0167 age - 9.001 FEV1 +0 F E V 1
2  (FEV1≤2.93)
= 65.69 - 0.0167 age - 30.152 FEV1 + 3.6095 FEV1
2  (2.93<FEV1≤4.14)
= 3.82 - 0.0167 age - 0.266 FEV1 +0 F E V 1
2  (FEV1>4.14)
Slope90 = 14.81 - 0.0160 age - 3.523 FEV1 +0 F E V 1
2  (FEV1≤2.93)
= 26.48 - 0.0160 age - 11.483 FEV1 + 1.3584 FEV1
2  (2.93<FEV1≤4.14)
= 3.19 - 0.0160 age - 0.236 FEV1 +0 F E V 1
2  (FEV1>4.14)
Slope75 = 4.90 - 0.0056 age - 0.997 FEV1 +0 F E V 1
2  (FEV1≤2.93)
= 7.53 - 0.0056 age - 2.796 FEV1 + 0.3071 FEV1
2  (2.93<FEV1≤4.14)
= 2.27 - 0.0056 age - 0.253 FEV1 +0 F E V 1
2  (FEV1>4.14)
Slope50 = 3.03 - 0.0039 age - 0.642 FEV1 +0 F E V 1
2  (FEV1≤2.93)
= 4.77 - 0.0039 age - 1.828 FEV1 + 0.2025 FEV1
2  (2.93<FEV1≤4.14)
= 1.30 - 0.0039 age - 0.152 FEV1 +0 F E V 1
2  (FEV1>4.14)
Table 3: Percentiles of methacholine slope* among men and women of the reference sample, SAPALDIA cross-sectional study, 1991
minimum P5 P10 P25 P50 P75 P90 P95 maximum
men (n = 
612)
-2.81 -0.55 -0.25 0.13 0.48 0.98 1.60 2.25 40.5
women (n = 
955)
-3.69 -0.13 0.06 0.41 0.90 1.67 3.25 5.72 78.5
entire 
reference 
sample (n = 
1567)
-3.69 -0.30 -0.07 0.26 0.72 1.41 2.40 4.85 78.5
* final %decrease in FEV1 from baseline divided by highest dose of methacholine administeredRespiratory Research 2005, 6:131 http://respiratory-research.com/content/6/1/131
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on BHR has not been consistently documented in the lit-
erature [2,5,11-13,16].
Our percentile equations may be used in epidemiological
studies to define more valid individual measures of
responsiveness (i.e. severity) because they incorporate
inherent confounding factors such as age and pre-test air-
way calibre. Moreover, the equations may enable clini-
cians to assess the degree of bronchial responsiveness in
their patients with greater validity. We provide a simple
Excel file enabling the computation of the percentile of a
subject's bronchial responsiveness provided that this
value lies between the 50th and the 95th percentile of the
distribution in our adult reference population.
In clinical practice, methacholine challenge is currently
used primarily to exclude asthma in atypical situations,
being recognized as a useful but imprecise test. Using the
90th percentile as a "cut-off" level for identifying asthmat-
ics in our sample of subjects with self-reported physician
diagnosed asthma provided a sensitivity of 51.1% which
did not differ between sexes; this percentage was very sim-
ilar to the percentage of subjects with a fall of 20% or
more during the methacholine test in the same popula-
tion (50.9%), where a significant difference was, however,
present between sexes (58.8% in women vs. 43.8% in
men). We therefore hypothesize that our equations and
index provide a more valid individual marker of the clin-
ical severity, enabling better characterization and quanti-
fication of bronchial responsiveness. While receiver
operator characteristic (ROC) studies would be needed to
evaluate the best "cut-off" percentile for asthma diagnosis,
using the 90 th percentile yielded the same sensitivity in
our subsample of asthmatics as the PD20 criterion in a
similar study population of subjects with self-reported
physician diagnosed asthma [30].
Conclusion
The present study provides equations for four relevant
percentiles of methacholine slope (defined according to
O'Connor) depending on the age and baseline FEV1 in an
adult reference population of non-obstructive and non-
atopic persons. In addition to the fact that such models
may help to better understand the underlying mecha-
nisms of BHR, they may be of use in future epidemiolog-
ical studies to better identify subjects whose bronchial
hyperreactivity is caused by extrinsic factors or by obstruc-
tive or atopic conditions. It may be of interest to both cli-
nicians and epidemiologists that the sensitivity of our
method in identifying subjects with a doctor's diagnosis
of asthma is the same in men and women whereas the tra-
ditional method based on PD20 has a lower sensitivity in
men. More generally, our equations may help physicians
to better characterize and follow bronchial responsiveness
of individual patients, based on simple predictive factors.
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